Roivant Sciences ROIV
NASDAQ ROIV
$36.30 -0.54 (-1.47%)
At close: Aug 21, 2026 · 4:00 PM EDT

Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2026)

Roivant Sciences' (ROIV) quarterly Income from Non-Controlling Interests came in at -$150.9 million in Q4 2025, down 8.67% YoY from -$165.2 million in Q4 2024, and down 187.29% on a QoQ basis from -$52.5 million in Q3 2025.

Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends

Roivant Sciences (ROIV) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$150.9 million in Q4 2025.

  • Quarterly Income from Non-Controlling Interests fell 8.67% year-over-year to -$150.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$392.8 million (down 25.6% YoY) and the FY2026 annual result came in at -$98.1 million, up 46.88% from the prior year.
  • Income from Non-Controlling Interests eased to -$150.9 million in Q4 2025, from -$52.5 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$17.2 million in Q3 2021 to a low of -$150.9 million in Q4 2025.
  • A 5-year average of -$56.6 million and a median of -$49.7 million in 2024 frame the typical range for Income from Non-Controlling Interests.
  • The widest YoY moves for Income from Non-Controlling Interests: up 5.2% in 2021, down 299.13% in 2021.
  • Tracing ROIV's Income from Non-Controlling Interests over 5 years: stood at -$57.6 million in 2021, then plunged by 37.47% to -$79.2 million in 2022, then dropped by 9.03% to -$86.3 million in 2023, then tumbled by 60.82% to -$138.9 million in 2024, then declined by 8.67% to -$150.9 million in 2025.
  • The last three Income from Non-Controlling Interests figures came in at -$150.9 million (Q4 2025), -$52.5 million (Q3 2025), and -$50.6 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - 63.60 Mn
10 Roivant Sciences 26.20 Bn 26.20 Bn 1.16 Mn -100.77 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -100.77 Mn
Dec 31, 2025 -150.89 Mn
Sep 30, 2025 -52.52 Mn
Jun 30, 2025 -50.56 Mn
Dec 31, 2024 -138.85 Mn
Sep 30, 2024 -49.74 Mn
Jun 30, 2024 -37.81 Mn
Dec 31, 2023 -86.34 Mn
Sep 30, 2023 -26.79 Mn
Jun 30, 2023 -36.03 Mn
Dec 31, 2022 -79.19 Mn
Sep 30, 2022 -24.33 Mn
Jun 30, 2022 -21.98 Mn
Dec 31, 2021 -57.60 Mn
Sep 30, 2021 -17.16 Mn
Jun 30, 2021 -18.90 Mn
Dec 31, 2020 -14.57 Mn
Sep 30, 2020 -18.10 Mn
Jun 30, 2020 -4.73 Mn